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vention to improve treatment guideline adherence would increase compliance
with recommendations.
Health Care Use & Policy Studies – Equity and Access
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EVALUATING THE PERFORMANCE OF AN INNOVATIVE PUBLIC HEALTH
INSURANCE: THE CASE OF A DECENTRALIZED PROVINCE IN ARGENTINA
Maceira D
CEDES, Buenos Aires, Argentina
OBJECTIVES: In Argentina, the public health system is deeply decentralized and
organized mainly at the provincial level. In this context, differences regarding
income distribution and access to health services require the creation of regulatory
devices and State intervention. One of the answers provided by the Buenos Aires
Health Ministry was the creation of Provincial Public Health Insurance. This pro-
gram included an innovative mechanism of human resources payment for the
public sector– a capitated system with the possibility to generate a plus over the
fixed salary- and aimed to reach the coverage of 2.4 million of citizens. The object
of this research is to analyze the performance of the strategy in terms of focaliza-
tion and development of preventive tasks associated to a higher quality at the
primary healthcare level.METHODS: A database of 1.7 million of consultations in
59 municipalities during the period 2004 to 2006 was analyzed, considering the
evolution of preventive and curative consultations. Logistic regression models
were implemented to determine the variables conditioning those tendencies.
RESULTS: The programwas appropriately focalized in poormunicipalities. Preven-
tive consultations increased 107% during the three-year period, and curative con-
sultations decreased by 56%. Preventive consultations were significantly associ-
atedwith young and female patients, as well as younger physicians. Also, poor and
populatedmunicipalities showed high associations with preventive consultations.
Differences between municipalities were relevant, showing significant associa-
tions on both signs. CONCLUSIONS: The insurance’s hiring and payment mecha-
nisms, result to be innovative and successful in the context of public health sub-
sector, conditioning the professionals to increase their efforts towards higher
quality preventive care. The strategymight be seen as one of the instruments with
the potential to enhance care quality and performance. Nevertheless, municipali-
ties show particular characteristics regarding their management and administra-
tive structures that affect the success of the program.
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CAN PRICING SCHEMES IMPROVE MARKET ACCESS FOR INNOVATIVE HIGH
PRICED DRUGS?
Anastasaki E, Colasante W, Imbeah-Ampiah R
PriceSpective Ltd., London, UK
OBJECTIVES: European payers are facing high levels of uncertainty about the value
of innovative drugs and their budget impact. These uncertainties are related to
both the drug’s actual usage such as dosing requirements as well as external fac-
tors such as patients’ clinical response and drug’s relative effectiveness. Over the
years, pricing schemes have been proposed to increase budget predictability. Due
to the varying perceptions of attractiveness, these schemes are not similarly ad-
opted across Europe. The research assessed the attractiveness of various schemes
as a way to reduce budget impact uncertainties and improve patient access to
innovative high priced drugs. METHODS: Both primary and secondary research
was conducted. The secondary research of published data, such as payers’ assess-
ments of pricing schemes and countries’ past policies allowed us to develop a
framework to understand the relative weights of the factors affecting payers’ un-
certainty regarding innovative-high priced drugs. The framework was then vali-
dated through qualitative primary research. RESULTS: The results revealed payers’
preference towards the cost per cycle proposition, because of its ease of implemen-
tation. Nevertheless, of the countries examined, only the UK and Italy were expe-
rienced with pricing schemes. Few others appeared to be relatively open to
schemes, sometimes at the local level and/or when more traditional approaches
are present.Most countrieswere very resistant to pricing schemes, primarily due to
the perceived complexity of schemes management and the transparency associ-
ated with it. Respondents’ opinions regarding pricing schemes also varied in terms
of the line of therapy they are targeted to. CONCLUSIONS: The heterogeneity of
Europemakes it difficult to have one scheme fit all. Schemes can reduce uncertain-
ties associated with therapy outcomes and budgetary expenditures; however pay-
ers are not willing to take additional risks associated with pricing schemes for
innovative high price drugs and prefer traditional straight discounts.
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REVIEW OF HIGHLY SPECIALIZED MEDICAL SERVICES IN KAZKAHSTAN
WITHIN AN INTRODUCTIN OF UNIFIED NATIONAL HEALTH SYSTEM
Yergaliyev K, Issayeva R, Umralin T
Ministry of Health of Republic of Kazakhstan, Astana, Kazakhstan
OBJECTIVES: As a consequence of the sweeping reforms in 2010 Kazakhstan has
introduced newly Unified National Health System (UNHS), which aims at improv-
ing the health of citizens through free choice of doctors andmedical organizations,
and introduction of new financial models and economic incentives for health care
providers, among others. Within UNHS reimbursement of highly specialized med-
ical services (HSMS) is based on increased tariffs. According to Law of Kazakhstan,
HSMS are services provided using new (high) health technologies. Objectives for
the paper were to review current condition of HSMS in the country, to identify
problems and to provide appropriate recommendations to meet needs of evolving
UNHS.METHODS: Retrospective analysis of health services provided by Secondary
care regional medical centers (Regional centers) (n848) and Republican level ter-
tiary care medical centers (Republican center) (n22) over 10 months in 2010, re-
view of regulatory documents related to HSMS. RESULTS: 6% of Regional centers
and 59% of Republican centers provide HSMS. Only 12% of case mix of Republican
center is HSMS. A list of HSMS technologies that is approved by Ministry of Health
mostly consists of surgery protocols (94%). There are no clear criteria to define
HSMS. Republican centers have transferred 37 high technologies to Regional
centers. CONCLUSIONS: Introduction of UNHS created a base for competitive en-
vironment in Kazakh Healthcare system. First time in a history, Regional centers
have started to provide HSMS and Republican centers report about significant de-
cline in a number of patients that need HSMS and reduction of waiting list. As a
result, an access of Kazakh population to HSMS has improved. These findings have
shown an urgent need for health technology assessment methodology and tools,
as it helps to define truly effective health technology and to manage scarce gov-
ernment budget for health services.
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ANALYSIS OF PHARMACISTS’ INTERVENTIONS ON ELECTRONIC VERSUS
TRADITIONAL PRESCRIPTIONS IN TWO COMMUNITY PHARMACIES
Gilligan A, Miller K, Mohney A, Montenegro C, Schwarz J, Warholak TL
University of Arizona, Tucson, AZ, USA
OBJECTIVES: The purpose of this study was to: 1) measure the incidence of pre-
scription problems that require pharmacist intervention; 2) determine the types
and relative frequency of prescription conveyance which contain problems that
require pharmacist intervention; and 3) estimate the pharmacy personnel time and
related practice expenses for prescriptions requiring intervention.METHODS: This
prospective study utilized an adaptation of the medication therapy intervention
(MTI) data collection form. Data were collected at two chain grocery store pharma-
cies by directly observing pharmacists for 3weeks, during the hours of 9am to 6pm.
Information recorded with each intervention included the type of prescription,
medication in question, reasons for intervention, intervention outcome, and time
spent performing intervention. Chi square analysis was conducted to compare
percentage of intervention rates between prescription conveyances. Kruskal-Wal-
lis rank test was utilized to compare the time on task values for the interventions.
Poisson regressionwas used in order to determine if significant differences existed
among the total number of interventions per group. RESULTS: Pharmacists re-
viewed 1678 new prescriptions and intervened on 157 (9.4%) over a 13 day period. A
total of 12 hours and 11 minutes was required to perform all interventions for an
overall average of 4.79 (SD0.34) minutes per intervention. Percentage of interven-
tion rates between prescription conveyances was not statistically significant
(p0.21). The time on task values for the interventions were also not statistically
significant (p0.39). However, compared with handwritten interventions, e-pre-
scribing interventions occurred 1.57 times less (p0.0001), faxed interventions oc-
curred 1.52 times less (p0.0001), and verbal interventions occurred 2.05 times less
frequently (p0.001), on average. CONCLUSIONS: E-prescribing interventions oc-
curred less frequently comparedwith handwritten interventions, whichmay pres-
ent a potential benefit. Future efforts to develop and enhance e-prescribing are
needed to add measurable value to patient care.
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IMPACT OF PHARMACY AND MEDICAL PLAN INTEGRATION ON OVERALL
MEDICAL COSTS
Bunz TJ, Nguyen HV, Regine ML
CIGNA HealthCare, Bloomfield, CT, USA
OBJECTIVES: Studies published by Aetna and Health Partners have demonstrated
the value of integrated medical and pharmacy benefits in their populations. Com-
bined coverage provides the opportunity for coordinated patient outreach and
aligned policy decisions. The purpose of this analysis is to determine if integrated
benefits result in lower total medical costs when compared to plans that utilize a
carve-out pharmacy benefit.METHODS:A retrospectivematched cohort studywas
utilized in order to compare the total medical costs associated with customers in
integrated health plans with customers with a carve-out PBM. Individual custom-
ers were included if they were continuously enrolled for at least 12 months within
the same plan type, had a full set of demographic, risk, and clinical data, and were
between the ages of 18 and 65. The two groups were matched based on demo-
graphic, comorbidity, and employer characteristics. RESULTS: This analysis
matched 39,896 customers in 2007 (19,948 in each group) and 151,144 customers in
2008 (75,572 in each group) for the final analysis. Medical costs were $13.77 (p-value
0.067) and $11.39 (p-value 0.006) per customer permonth lower for customerswith an
integrated pharmacy benefit as compared to carve-out customers in 2007 and 2008
respectively. In 2007 and 2008 the bulk of the savings ($6 and $7 pcpm respectively)
were associated with lower utilization of outpatient services. CONCLUSIONS:When
controlling for demographic, clinical, and employment characteristics, there is a
significant savings associated with integrating medical and pharmacy benefits.
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DECISION MAKING IN BRAZIL BASED ON HEALTH TECHNOLOGY ASSESSMENT:
THE GOOD, THE BAD, AND THE FUTURE
Machado M1, Fonseca E2, Fonseca M3
1GlaxoSmithKline Brazil, Rio de Janeiro, Brazil, 2Federal University of São Paulo, São Paulo,
Brazil, 3Axia.Bio, São Paulo, Brazil
OBJECTIVES:Despite the premise of universal access supported by its Constitution,
the Brazilian healthcare system is subject to similar financing issues as in other
jurisdictions worldwide. A misunderstanding between Constitutional rights and
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healthcare budget restrictions leads to the controversial model of procedural jus-
tice. The objective was to describe the characteristics of the current decision-mak-
ing scenario in Brazil using Health Technology Assessment (HTA), its main actors,
consequences and future opportunities.METHODS: A review of HTA regulation in
Brazil and the published literature on the topic was conducted. The Brazilian HTA
model was discussed and strengths and weaknesses highlighted. RESULTS: Over
the years, drug expenditures and healthcare demand have grown exponentially in
Brazil. In 2006, the Brazilian Ministry of Health (MoH) created a HTA process (Reg-
ulation #152). The main objective was to align the dynamics of health technology
decisions with population social needs, epidemiological profile, and healthcare
system financing characteristics. The principal components are a clinical review
and economic analysis of technologies under evaluation. Multiple government
players are involved, but no reference to external involvement. Health technology
decisions take into consideration: a) the relevance/impact of the technologywithin
the system, and b) the safety, effectiveness, and cost-effectiveness of the appraised
technologies. No reference was found to what is considered cost-effective/efficient
for the system. Proposed HTA regulation changes are underway and include: rapid
response, societal engagement (i.e., public consultation of MoH decisions), and
changes in decision determinants (i.e., economic impact to be least important).
CONCLUSIONS: Currently, Brazil holds an informed health technology decision-
making process. However, clear/objective parameters for aiding decisions have not
been described or yet proposed. Uncertainty still remains with regards to efficient
health technology decisions. Current initiatives to improve HTA process are con-
troversial. In the future, HTA could serve as a mediator between constitutional
obligations and current budgetary restrictions in the country.
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CATASTROPHIC INJURY-RELATED ENROLLMENT AND COSTS IN A STATE
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1University of Oklahoma, Tulsa, OK, USA, 2Pacific Institute for Research & Evaluation, Columbia,
MD, USA
OBJECTIVES: 1) Calculate the number of enduring enrollees who entered a state
Medicaid program because of catastrophic injury, and 2) estimate lifetime Medic-
aid costs of the enrollees. METHODS: De-identified administrative data from a
state Medicaid program that included paid fee-for-service claims for medical ser-
vices and prescription medications dated between 2000 and 2005, as well as an
eligibility file listing enrollment periods of recipients, were the data source. The
study is a prospective, longitudinal, historical cohort design. Inpatient hospitaliza-
tion claims with a diagnosis of injury in any of the first three diagnosis fields were
extracted. The study sample comprised recipients less than 65 years old whose
eligibility forMedicaid began on the first of themonth inwhich ahospitalization for
injury occurred. The cohort was followed for the duration of each recipient’s initial
eligibility period. Costs were discounted at 3% and from the perspective of
Medicaid. RESULTS: Eligibility of 2089 recipients started the month they were hos-
pitalized for injury over the study period, a rate of approximately 1.1 per 1000
recipients per year and 6.0 per 1000 new recipients per year. Among the 2089
cohort, 364 (17%) recipients had open-ended eligibility that could last the duration
of life; a majority of whom were over 20 years old. Adults with injury with open-
ended eligibility accounted for approximately 1.5 per 1000 new adult recipients per
year. The estimated lifetime Medicaid cost for medical services and prescription
drugs for a 30-year old male recipient with injury with lifetime eligibility equaled
$76,833. CONCLUSIONS: Catastrophic injury can lead an individual to enter Med-
icaid. One in six entrantsmay require lifetimeMedicaid coverage. In this study, the
rate of lifetime eligibility for Medicaid occurred with low incidence. However, the
cost of injury to the Medicaid program often greatly exceeds the cost of injury
treatment alone.
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A REGISTRY PERSPECTIVE OF OF HOSPITAL DISCHARGE COSTS: PILOT RESULTS
OF THE 10 MOST FREQUENT DIAGNOSIS AND PROCEDURES OF THE
ARGENTINE-HEALTH CARE COST AND UTILIZATION PROJECT (A-HCUP)
Insua JT1, Giunta D2, Ioli P3, Villalon R1
1Hospital Universitario Austral, Universidad Austral, Derqui, Argentina, 2Hospital Italiando de
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OBJECTIVES: The priority of hospital health care results and costs in transitional
countries, needs to avoid non-standardized, unreliable or non-existent data. To
achieve this goal we developed a hospital discharge registry in Argentina
METHODS:AMinimumDischarge Data Set (MDS), designed and extracted from a 1
year output, 2007-2008, of 3 non-profit hospitals with information systems. Cost
and result indicators, harmonized according to WHO and HCUPS (USA) terminol-
ogy, groupers (Clinical Classification Software-CCS single level-SL, 2009) of primary
diagnosis (D1) and procedures (P1), (#CCS [descriptive term]), total costs (CT$)
andmedian per discharge cost ($, 25P-75P-percentiles), in international dollars PPP,
(UN Data: 1Arg$ 1.608 PPP, 2008) were obtained, generating a Pareto ranking of 10
most frequent CCS discharge codes. RESULTS: 58116 discharges with 17125 Dx1
and 9163 Px1 where obtained. The first 10 CCS-SL Dx1 were: #218 [living recently
born] ($ 229, 117-251); #45 [chemotherapy, radiotherapy], ($4705; 1946-8212); #196
[pregnancy and normal delivery], ($ 4.829; 2.958-5.985); # 149 [biliary disorders], ($
5.932; 4.700-9.268); #122 [Pneumonia], ($ 2.193; 1.280- 4.856); #101 [coronary athero-
sclerosis], ($ 22.090; 5.586-38.692); #108 [congestive heart failure, non- hyperten-
sive], ($ 1.918; 989-6.156); # 195 [other complications of delivery], ($ 6.940; 3.971-
8.341); #144 [unspecified neoplasia], ($ 12.975; 4.511-28.960), y #203 [osteoarthritis],
($ 13.490; 8.753- 20.305); comprised 29,4% of discharges, with a CT$ $ 142.852.765
(23,7%). The procedure related CCS of delivery are cesarean section (#134) and other
birth related (#137,#135) represented 6.95% of primary procedures (P1). The most
costly procedure was P1 # ($ 15.834; 4.860-32.168). The first 10 P constitutes a
17,6% of discharges and a 23.9% of procedure CT$. CONCLUSIONS: Transitional
countries can develop this information, but harmonization is required. We ob-
tained 30% of total costs (CT$) and per discharge costs ($) with a Pareto rank. Future
studies need to improve within country generalizability of results.
PHP38
UTILIZATION, PRICE AND SPENDING OF ANTI-TUMOR NECROSIS FACTOR
BIOLOGICS IN THE UNITED STATES MEDICAID PROGRAM
Atzinger C, Guo JJ
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES:Anti-TNF (tumor necrosis factor) drugs are extremely effective for the
treatment of many auto-immune diseases such as rheumatoid arthritis, multiple
sclerosis, and psoriasis. The high price of these medications has a significant im-
pact on the Medicaid budget. The objective was to determine the trends in utiliza-
tion, price and spending for anti-TNF biologics and to analyze the market share
competition between biologics. METHODS: A retrospective, descriptive analysis
was conducted using national summary files from the Medicaid State Drug Utili-
zation Data from 1998 to 2010. Quarterly number of prescriptions and reimburse-
ment data were calculated for the trends analysis. Study drugs included all brand
and generic names of anti-TNF biologics (e.g., abatacept, adalimumab, anakinra,
certolizumab, etanercept, golimumab, infliximab, and rituximab). Market shares
for biologics were quantified and compared between 2006 and 2010. The quarterly
price per prescription was calculated by dividing the total reimbursement by the
total number of prescriptions. RESULTS: The data show an increase in the number
of prescriptions reimbursed over time. Etanercept is the most commonly pre-
scribed biologic in this class, followed by adalimumab. Medicaid has reimbursed
over $1 billion for etanercept, and $500 million for adalimumab. During the period
from 2006Q1 to 2010Q1, etanercept lost 35% of it’s market share. While all other
compounds increased their market share, etanercept lost 40% of its sales market
share. All study biologics have experienced an increase reimbursed price since
initial market entry after one year of entry into market. Older biologics like
etanercept and adalimumab increased over 100% and 60%, respectively. Certoli-
zumab which has only been on the market for two years has increased 15%.
CONCLUSIONS: Biologic medicines represent some of themost complex but costly
products. It will be critical to devise creative methods and incentives to control the
costs of these medicines without stifling the innovation.
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HEALTH CARE REFORMS UNDER ECONOMIC CRISIS: THE GREEK CASE
Kritikou P, Latsou D, Yfantopoulos J
National and Kapodistrian University of Athens, Athens, Greece
BACKGROUND: Since the establishment of the Greek National Health Care System
in 1983 several reforms have been legally introduced without being implemented.
The recent economic crisis aggravated the performance of the health care system
increasing the inefficiencies and the inequalities. OBJECTIVES: The aim of the
study is to perform a systematic review and critical appraisal of efficiency, quality,
effectiveness and equality of the Greek health care system since the 1980s.
METHODS: A systematic literature review was performed using the following da-
tabases: Center for Reviews and Dissemination (CRD), PubMed, ScienceDirect,
EconLit and EconPapers. The key words used are “Greece”, “health” and “health
care”. The retrieved articles searchedwere 338. Of these 73 paperswere included in
the study analyzing efficiency, equality, and effectiveness of the Greek health care
system over the period 1990-2011. The evolution of public and private health ex-
penditures in conjunction with GDP and health outcome indicators is concerned
using both descriptive and econometric models. RESULTS: The Greek health care
system is fragmented with a mix of public and private activities. Private financing
in Greece is the highest in the European Union with oligopolistic trends in private
hospitals and diagnostic centers. Satisfaction with public services is one of the
lowest in the EU27 countries. Informal payments constitute a significant share
creating distortions in the efficiency of the public sector. Furthermore, informal
payments are regressive imposing a higher economic burden in the lower income
classes. CONCLUSIONS: The systematic review highlights the persistent problems
of the Greek health care systemand signifies the importance of health care reforms
towards greater efficiency and convergence with the rest of the EU countries.
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THE CHANGING LANDSCAPE OF ORPHAN DRUG PROVISION IN THE EU5 AND
THE UNITED STATES
McConkey D
Double Helix Consulting, London, UK
OBJECTIVES: The global health care environment is in a considerable state of flux
with many national health systems undergoing some degree of reform. Orphan
drugs have historically been funded at a national level through different systems to
the rest of the pharmacopeia. With this in mind, the author set out to assess the
impact of healthcare reform on how orphan drugs are likely to be provided for in
the future.METHODS:This project involved a study of orphan drug provision in the
past and more recently, including both primary and secondary research elements.
Trends in the changing healthcaremarket and specific reformswere considered as
part of a prospective study on the orphan drug landscape. RESULTS: Orphan drug
provision usually utilises a separate infrastructure to manage the allocation of
funding, with this system insulated to a degree from general healthcare reform. In
countries where rare diseases are treated in specific institutions (e.g. Italy) there is
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